Jun 15, 2020
Neurocrine Biosciences to Present at the Bank of America Securities 2020 Napa Biopharma Conference
Jun 04, 2020
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
May 26, 2020
Neurocrine Biosciences to Present at the Jefferies Virtual Healthcare Conference
May 14, 2020
Neurocrine Biosciences to Present at the RBC Capital Markets 2020 Global Healthcare Conference
May 13, 2020
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
May 06, 2020
Neurocrine Biosciences Reports First Quarter 2020 Financial Results
Apr 27, 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Apr 16, 2020
Innovative Approaches to Healthcare Lead to the Psychedelic Biotech Market's Inception
Apr 15, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
Apr 03, 2020
Neurocrine Biosciences Provides COVID-19 Business Update
Feb 04, 2020
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
Feb 03, 2020
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors
Jan 20, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
Jan 06, 2020
Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020
Jan 01, 2020
Global endometriosis treatment market is expected to grow with a CAGR of 2.8% over the forecast period from 2019-2025
Dec 02, 2019
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
Nov 26, 2019
Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference
Nov 05, 2019
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
Nov 04, 2019
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
Oct 04, 2019
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress